Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials.
Lebwohl M, Warren RB, Sofen H, Imafuku S, Paul C, Szepietowski JC, Spelman L, Passeron T, Vritzali E, Napoli A, Kisa RM, Buck A, Banerjee S, Thaçi D, Blauvelt A.
Lebwohl M, et al. Among authors: paul c.
Br J Dermatol. 2024 Apr 17;190(5):668-679. doi: 10.1093/bjd/ljae014.
Br J Dermatol. 2024.
PMID: 38226713
Clinical Trial.